Dual CLL1/CD38 targeting CAR-T cell therapy - Gracell Biotechnology
Alternative Names: CLL1 and CD38 dual-target CAR-T injection - Gracell BiotechnologyLatest Information Update: 26 Feb 2024
At a glance
- Originator Gracell Biotechnology
- Developer 920th Hospital of Joint Logistics Support Force of Peoples Liberation Army of China; Gracell Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Acute myeloid leukaemia